MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.

International Journal of Biological Sciences
Yansong BianZhong Chen

Abstract

The serine-threonine kinase CK2 exhibits genomic alterations and aberrant overexpression in human head and neck squamous cell carcinomas (HNSCC). Here, we investigated the effects of CK2 inhibitor CX-4945 in human HNSCC cell lines and xenograft models. The IC50's of CX-4945 for 9 UM-SCC cell lines measured by MTT assay ranged from 3.4-11.9 μM. CX-4945 induced cell cycle arrest and cell death measured by DNA flow cytometry, and inhibited prosurvival mediators phospho-AKT and p-S6 in UM-SCC1 and UM-SCC46 cells. CX-4945 decreased NF-κB and Bcl-XL reporter gene activities in both cell lines, but upregulated proapoptotic TP53 and p21 reporter activities, and induced phospho-ERK, AP-1, and IL-8 activity in UM-SCC1 cells. CX-4945 exhibited modest anti-tumor activity in UM-SCC1 xenografts. Tumor immunostaining revealed significant inhibition of PI3K-Akt-mTOR pathway and increased apoptosis marker TUNEL, but also induced p-ERK, c-JUN, JUNB, FOSL1 and proliferation (Ki67) markers, as a possible resistance mechanism. To overcome the drug resistance, we tested MEK inhibitor PD-0325901 (PD-901), which inhibited ERK-AP-1 activation alone and in combination with CX-4945. PD-901 alone displayed significant anti-tumor effects in vivo, and the c...Continue Reading

Citations

Nov 14, 2015·Expert Opinion on Therapeutic Targets·Giorgio Cozza, Lorenzo A Pinna
Apr 8, 2016·Expert Opinion on Investigational Drugs·Paolo Bossi, Salvatore Alfieri
Nov 9, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Szu-Ting ChouJulia Y Ljubimova
Jan 31, 2017·Pharmaceuticals·Melissa M J ChuaIsabel Dominguez
Dec 6, 2017·PloS One·Melissa M J ChuaIsabel Dominguez
Jul 7, 2019·Journal of Experimental & Clinical Cancer Research : CR·Christian Borgo, Maria Ruzzene
Aug 26, 2018·Cancers·Jomnarong LertsuwanJutamaad Satayavivad
Dec 14, 2016·Oncology Reports·Kengo TakahashiSetsuro Komiya
Feb 15, 2021·Experimental Cell Research·Hu ZhouXiang Zhu
Jun 3, 2021·Journal of Clinical Medicine·Panagiotis GarantziotisEleni Frangou
Oct 15, 2020·Cellular Oncology (Dordrecht)·Claudio D'AmoreMauro Salvi

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
FCS
flow cytometry
FACS
xenograft
xenografts

Software Mentioned

GraphPad Prism
Jo
Flow

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
Yan SongWen-Yue Ji
© 2021 Meta ULC. All rights reserved